title: Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides.
abstract: The treatment strategy for vasculitis has changed dramatically over the last few years, but some major questions remain. Herein, after reviewing the literature, we provide answers to, or at least an analysis of, available evidence on 10 specific and practical questions concerning ANCA-associated vasculitis management.
authors.affiliation: Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, INSERM U1016, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, University of Paris Descartes, Paris, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Chaigne
authors.affiliation: Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, INSERM U1016, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, University of Paris Descartes, Paris, France. loic.guillevin@cch.aphp.fr.
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications / Q000188:drug therapy*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis; D015267:Churg-Strauss Syndrome / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D000069283:Rituximab / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D000069283:Rituximab